Allogene Therapeutics (ALLO) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed YD Bio (YDES) over the past year, gaining 6.5% versus a loss of 70.5%. Allogene Therapeutics is the larger company by market cap ($452.6 million vs $419.3 million), about 1.1 times the size, while YD Bio is growing revenue faster (+16.9% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | YDES |
|---|---|---|
| Share price | $1.31 | $5.92 |
| Market cap | $452.59M | $419.32M |
| 1-day change | -2.24% | -12.17% |
| YTD return | -4.38% | -51.44% |
| 1-year return | +6.50% | -70.53% |
| 5-year return | -91.72% | — |
| EPS (TTM) | $-0.66 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $596.82K |
| Revenue growth (YoY) | -100.00% | +16.94% |
| Net income (latest FY) | $-190.89M | $-8.31M |
| Gross margin | — | 28.05% |
| Operating margin | — | -883.31% |
| Net margin | — | -1392.61% |
| 52-week high | $4.46 | $22.00 |
| 52-week low | $1.04 | $1.70 |
| Distance from 52-week high | -70.63% | -73.09% |
| Analyst consensus | none | — |
| Avg. price target upside | +587.02% | — |
| Average volume | 5.66M | 289.85K |
| Shares outstanding | 345.49M | 70.83M |
| Employees | 150 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLO has outperformed YDES by 77.0 percentage points over the past year.
- YD Bio grew revenue faster in its latest fiscal year (+16.94% vs -100.00%).
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Healthcare · Biotechnology · 150 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Healthcare · Biotechnology · 13 employees
ALLO vs YDES FAQ
Which is bigger, Allogene Therapeutics or YD Bio?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $452.59M compared with $419.32M for YD Bio (YDES).
Which stock has performed better over the past year, ALLO or YDES?
ALLO returned +6.50% over the past 12 months, compared with -70.53% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and YD Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.